Targeting microRNAs in pathological hypertrophy and cardiac failure

Mini-Reviews in Medicinal Chemistry

Volumn 15, Issue 6, 2015, Pages 475-478

  Lv, Dongchao ^a   Liu, Jingqi ^a,b   Zhao, Cuimei ^b   Sun, Qi ^a   Zhou, Qiulian ^a   Xu, Jiahong ^b   Xiao, Junjie ^a,b  

^a SHANGHAI UNIVERSITY   (China)

^b TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Cardiac failure; MicroRNA; Pathological hypertrophy; Therapy

Indexed keywords

ANTAGOMIR; CALCINEURIN; MICRORNA; MICRORNA 1; MICRORNA 133; MICRORNA 155; MICRORNA 208; MICRORNA 21; MICRORNA 25; MICRORNA 652; MYOSIN HEAVY CHAIN BETA; UNCLASSIFIED DRUG;

ARTICLE; DOWN REGULATION; FIBROBLAST; HEART DEVELOPMENT; HEART FAILURE; HEART MUSCLE CELL; HEART MUSCLE CONTRACTILITY; HEART VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; NONHUMAN; PROTEIN EXPRESSION; UPREGULATION; ANIMAL; GENETICS; HEART MUSCLE; HYPERTROPHY; MOLECULARLY TARGETED THERAPY; PATHOLOGY; PROCEDURES;

ANIMALS; HEART FAILURE; HUMANS; HYPERTROPHY; MICRORNAS; MOLECULAR TARGETED THERAPY; MYOCARDIUM;

EID: 84929300954     PISSN: 13895575     EISSN: 18755607     Source Type: Journal    
DOI: 10.2174/1389557515666150324124751     Document Type: Article

References (50)

1. Papoutsidakis, N.; Deftereos, S.; Kaoukis, A.; Bouras, G.; Giannopoulos, G.; Theodorakis, A.; Angelidis, C.; Hatzis, G.; Stefanadis, C. MicroRNAs and the heart: small things do matter. Curr. Top. Med. Chem., 2013, 13, 216-30.
2. Braunwald, E. The war against heart failure: the Lancet lecture. Lancet, 2014, DOI: 10.1016/S0140-6736(14)61889-4.
3. Li, J.; Xu, J.; Cheng, Y.; Wang, F.; Song, Y.; Xiao, J. Circulating microRNAs as mirrors of acute coronary syndromes: MiRacle or quagMire? J. Cell Mol. Med., 2013, 17, 1363-70.
4. Xiao, J.; Liang, D.; Zhang, H.; Liu, Y.; Zhang, D.; Liu, Y.; Pan, L.; Chen, X.; Doevendans, P.A.; Sun, Y.; Liang, X.; Sluijter, J.P.; Chen, Y.H. MicroRNA-204 is required for differentiation of human-derived cardiomyocyte progenitor cells. J. Mol. Cell Cardiol., 2012, 53, 751-9.
5. Xu, J.; Zhao, J.; Evan, G.; Xiao, C.; Cheng, Y.; Xiao, J. Circulating microRNAs: novel biomarkers for cardiovascular diseases. Mol. Med. (Berl), 2012, 90, 865-75.
6. Gama-Carvalho, M.; Andrade, J.; Brás-Rosário, L. Regulation of Cardiac Cell Fate by microRNAs: Implications for Heart Regeneration. Cells, 2014, 3, 996-1026.
7. Matkovich, S.J. MicroRNAs in the Stressed Heart: Sorting the Signal from the Noise. Cells, 2014, 3, 778-801.
8. Bronze-da-Rocha, E. MicroRNAs expression profiles in cardiovascular diseases. Biomed. Res. Int., 2014, 2014, 985408.
9. Thum, T.; Catalucci, D.; Bauersachs, J. MicroRNAs: novel regulators in cardiac development and disease. Cardiovasc Res., 2008, 79, 562-70.
10. Wightman, B.; Ha, I.; Ruvkun, G. Posttranscriptional regulation of the heterochronic gene lin-14 by lin-4 mediates temporal pattern formation in C. elegans. Cell, 1993, 75, 855-62.
11. Han, J.; Lee, Y.; Yeom, K.H.; Kim, Y.K.; Jin, H.; Kim, V.N. The Drosha-DGCR8 complex in primary microRNA processing. Genes Dev., 2004, 18, 3016-27.
12. Davis-Dusenbery, B.N.; Hata, A. Mechanisms of control of microRNA biogenesis. J. Biochem., 2010, 148, 381-92.
13. Da Costa Martins, P.A.; De Windt, L.J. MicroRNAs in control of cardiac hypertrophy. Cardiovasc Res., 2012, 93, 563-72.
14. Zhao, Y.; Ransom, J.F.; Li, A.; Vedantham, V.; von Drehle, M.; Muth, A.N.; Tsuchihashi, T.; McManus, M.T.; Schwartz, R.J., Srivastava, D. Dysregulation of cardiogenesis, cardiac conduction, and cell cycle in mice lacking miRNA-1-2. Cell, 2007, 129, 303-17.
15. da Costa Martins, P.A.; Bourajjaj, M.; Gladka, M.; Kortland, M.; van Oort, R.J.; Pinto, Y.M.; Molkentin, J.D.; De Windt, L.J. Conditional dicer gene deletion in the postnatal myocardium provokes spontaneous cardiac remodeling. Circulation, 2008, 118, 1567-76.
16. Chen, J.F.; Murchison, E.P.; Tang, R.; Callis, T.E.; Tatsuguchi, M.; Deng, Z.; Rojas, M.; Hammond, S.M.; Schneider, M.D.; Selzman, C.H., Meissner, G.; Patterson, C.; Hannon, G.J., Wang, D.Z. Targeted deletion of Dicer in the heart leads to dilated cardiomyopathy and heart failure. Proc. Natl. Acad. Sci. U.S.A., 2008, 105, 2111-6.
17. Sayed, D.; Abdellatif, M. MicroRNAs in development and disease. Physiol. Rev., 2011, 91, 827-87.
18. Zhao, Y.; Samal, E.; Srivastava, D. Serum response factor regulates a muscle-specific microRNA that targets Hand2 during cardiogenesis. Nature, 2005, 436, 214-20.
19. Mishima, Y.; Stahlhut, C.; Giraldez, A.J. miR-1-2 gets to the heart of the matter. Cell, 2007, 129, 249-9.
20. van Rooij, E.; Sutherland, L.B.; Liu, N.; Williams, A.H.; McAnally, J.; Gerard, R.D.; Richardson, J.A.; Olson, E.N. A signature pattern of stress-responsive microRNAs that can evoke cardiac hypertrophy and heart failure. Proc. Natl. Acad. Sci. U.S.A., 2006, 103, 18255-60.
21. Thum, T.; Galuppo, P.; Wolf, C.; Fiedler, J.; Kneitz, S.; van Laake, L.W.; Doevendans, P.A.; Mummery, C.L., Borlak, J.; Haverich, A.; Gross, C.; Engelhardt, S.; Ertl, G.; Bauersachs, J. MicroRNAs in the human heart: a clue to fetal gene reprogramming in heart failure. Circulation, 2007, 116, 258-67.
22. Luo, X.; Zhang, H.; Xiao, J.; Wang, Z. Regulation of human cardiac ion channel genes by microRNAs: theoretical perspective and pathophysiological implications. Cell Physiol Biochem, 2010, 25, 571-86.
23. Topkara, V.K.; Mann, D.L. Clinical applications of miRNAs in cardiac remodeling and heart failure. Per. Med., 2010, 7, 531-48.
24. Sayed, D.; Hong, C.; Chen, I.Y.; Lypowy, J.; Abdellatif, M. MicroRNAs play an essential role in the development of cardiac hypertrophy. Circ. Res., 2007, 100, 416-24.
25. Hua, Y.; Zhang, Y.; Ren, J. IGF-1 deficiency resists cardiac hypertrophy and myocardial contractile dysfunction: role of microRNA-1 and microRNA-133a. J. Cell Mol. Med., 2012, 16, 83-95.
26. Ikeda, S.; He, A.; Kong, S.W.; Lu, J.; Bejar, R.; Bodyak, N.; Lee, K.H.; Ma, Q.; Kang, P.M.; Golub, T.R., Pu, W.T. MicroRNA-1 negatively regulates expression of the hypertrophy-associated calmodulin and Mef2a genes. Mol. Cell Biol., 2009, 29, 2193-204.
27. Karakikes, I.; Chaanine, A.H.; Kang, S.; Mukete, B.N.; Jeong, D.; Zhang, S.; Hajjar, R.J.; Lebeche, D.Therapeutic cardiac-targeted delivery of miR-1 reverses pressure overload-induced cardiac hypertrophy and attenuates pathological remodeling. J. Am. Heart Assoc., 2013, 2, e000078.
28. Care, A.; Catalucci, D.; Felicetti, F.; Bonci, D.; Addario, A.; Gallo, P.; Bang, M.L.; Segnalini, P.; Gu, Y.; Dalton, N.D., Elia, L.; Latronico, M.V.; Hoydal, M.; Autore, C.; Russo, M.A.; Dorn, G.W. 2nd Ellingsen, O.; Ruiz-Lozano, P.; Peterson, K.L.; Corce, C.M.; Peschle, C.; Condorelli, G. MicroRNA-133 controls cardiac hypertrophy. Nat. Med., 2007, 13, 613-8.
29. Li, Q.; Lin, X.; Yang, X.; Chang, J. NFATc4 is negatively regulated in miR-133a-mediated cardiomyocyte hypertrophic repression. Am. J. Physiol. Heart Circ. Physiol., 2010, 298, H1340-7.
30. van Rooij, E.; Quiat, D.; Johnson, B.A.; Sutherland, L.B.; Qi, X.; Richardson, J.A.; Kelm, R.J. Jr.; Olson, E.N. A family of microRNAs encoded by myosin genes governs myosin expression and muscle performance. Dev. Cell, 2009, 17, 662-73.
31. Callis, T.E.; Pandya, K.; Seok, H.Y.; Tang, R.H.; Tatsuguchi, M.; Huang, Z.P.; Chen, J.F.; Deng, Z.; Gunn, B.; Shumate, J.; Willis, M.S.; Selzman, C.H.; Wang, D.Z. MicroRNA-208a is a regulator of cardiac hypertrophy and conduction in mice. J. Clin. Invest., 2009, 119, 2772-86.
32. van Rooij, E.; Sutherland, L.B.; Qi, X.; Richardson, J.A.; Hill, J.; Olson, E.N. Control of stress-dependent cardiac growth and gene expression by a microRNA. Science, 2007, 316, 575-9.
33. Montgomery, R.L.; Hullinger, T.G.; Semus, H.M.; Dickinson, B.A.; Seto, A.G.; Lynch, J.M.; Stack, C.; Latimer, P.A.; Olson, E.N.; van Rooij, E. Therapeutic inhibition of miR-208a improves cardiac function and survival during heart failure. Circulation, 2011, 124, 1537-47.
34. Condorelli, G.; Latronico, M.V.; Cavarretta, E. microRNAs in cardiovascular diseases: current knowledge and the road ahead. J. Am. Coll. Cardiol., 2014, 63, 2177-87.
35. De Rosa, S.; Curcio, A.; Indolfi, C. Emerging role of microRNAs in cardiovascular diseases. Circ. J., 2014, 78, 567-75.
36. Bush, E.W.; van Rooij, E. miR-25 in heart failure. Circ. Res., 2014, 115, 610-2.
37. Wahlquist, C.; Jeong, D.; Rojas-Muñoz, A.; Kho, C.; Lee, A.; Mitsuyama, S.; van Mil, A.; Park, W.J.; Sluijter, J.P.; Doevendans, P.A.; Hajjar, R.J.; Mercola, M. Inhibition of miR-25 improves cardiac contractility in the failing heart. Nature, 2014, 508, 531-5.
38. Martinez-Fernandez, A. MicroRNA therapy for the failing heart. Circ. Cardiovasc Genet, 2014, 7, 393-4.
39. Tian, F.J.; An, L.N.; Wang, G.K.; Zhu, J.Q.; Li, Q.; Zhang, Y.Y.; Zeng, A.; Zou, J.; Zhu, R.F.; Han, X.S.; Shen, N.; Yang, H.T.; Zhao, X.X.; Huang, S.; Qin, Y.W.; Jing, Q. Elevated microRNA- 155 promotes foam cell formation by targeting HBP1 in atherogenesis. Cardiovasc Res., 2014, 103, 100-10.
40. Heymans, S.; Corsten, M.F.; Verhesen, W.; Carai, P.; van Leeuwen, R.E.; Custers, K.; Peters, T.; Hazebroek, M.; Stöger, L.; Wijnands, E.; Janssen, B.J.; Creemers, E.E.; Pinto, Y.M.; Grimm, D.; Schürmann, N.; Vigorito, E.; Thum, T.; Stassen, F.; Yin, X.; Mayr, M.; de Windt, L.J.; Lutgens, E.; Wouters, K.; de Winther, M.P.; Zacchigna, S.; Giacca, M.; van Bilsen, M.; Papageorgiou, A.P.; Schroen, B. Macrophage microRNA-155 promotes cardiac hypertrophy and failure. Circulation, 2013, 128, 1420-32.
41. Seok, H.Y.; Chen, J.; Kataoka, M.; Huang, Z.P.; Ding, J.; Yan, J.; Hu, X.; Wang, D.Z. Loss of MicroRNA-155 protects the heart from pathological cardiac hypertrophy. Circ Res, 2014, 114, 1585-95.
42. Matkovich, S.J.; Hu, Y.; Dorn, G.W. 2nd. Regulation of cardiac microRNAs by cardiac microRNAs. Circ. Res., 2013, 113, 62-71.
43. Lin, R.C.; Weeks, K.L.; Gao, X.M.; Williams, R.B.; Bernardo, B.C.; Kiriazis, H.; Matthews, V.B.; Woodcock, E.A.; Bouwman, R.D.; Mollica, J.P.; Speirs, H.J.; Dawes, I.W.; Daly, R.J.; Shioi, T.; Izumo, S.; Febbraio, M.A.; Du, X.J.; McMullen, J.R. PI3K(p110 alpha) protects against myocardial infarction-induced heart failure: identification of PI3K-regulated miRNA and mRNA. Arterioscler Thromb. Vasc. Biol., 2010, 30, 724-32.
44. Bernardo, B.C.; Nguyen, S.S.; Winbanks, C.E.; Gao, X.M.; Boey, E.J.; Tham, Y.K.; Kiriazis, H.; Ooi, J.Y.; Porrello, E.R.; Igoor, S.; Thomas, C.J.; Gregorevic, P.; Lin, R.C.; Du, X.J.; McMullen, J.R. Therapeutic silencing of miR-652 restores heart function and attenuates adverse remodeling in a setting of established pathological hypertrophy. FASEB J., 2014, 28, 5097-110.
45. Bang, C.; Batkai, S.; Dangwal, S.; Gupta, S.K.; Foinquinos, A.; Holzmann, A.; Just, A.; Remke, J.; Zimmer, K.; Zeug, A.; Ponimaskin, E.; Schmiedl, A.; Yin, X.; Mayr, M.; Halder, R.; Fischer, A.; Engelhardt, S.; Wei, Y.; Schober, A.; Fiedler, J.; Thum, T. Cardiac fibroblast-derived microRNA passenger strandenriched exosomes mediate cardiomyocyte hypertrophy. J. Clin. Invest., 2014, 124, 2136-46.
46. Bernardo, B.C.; Charchar, F.J.; Lin, R.C.; McMullen, J.R. A microRNA guide for clinicians and basic scientists: background and experimental techniques. Heart Lung Circ., 2012, 21, 131-42.
47. Port, J.D.; Sucharov, C. Role of microRNAs in cardiovascular disease: therapeutic challenges and potentials. J. Cardiovasc Pharmacol., 2010, 56, 444-53.
48. Janssen, H.L.; Reesink, H.W.; Lawitz, E.J.; Zeuzem, S.; Rodriguez-Torres, M.; Patel, K.; van der Meer, A.J.; Patick, A.K.; Chen, A.; Zhou, Y.; Persson, R.; King, B.D.; Kauppinen, S.; Levin, A.A.; Hodges, M.R. Treatment of HCV infection by targeting microRNA. N. Engl. J. Med., 2013, 368, 1685-94.
49. Wang, R.; Ma, J.; Wu, Q.; Xia, J.; Miele, L.; Sarkar, F.H.; Wang, Z. Functional role of miR-34 family in human cancer. Curr. Drug Targets, 2013, 14, 1185-91.
50. Kwekkeboom, R.F.; Lei, Z.; Doevendans, P.A.; Musters, R.J.; Sluijter, J.P. Targeted delivery of miRNA therapeutics for cardiovascular diseases: opportunities and challenges. Clin. Sci. (Lond), 2014, 127, 351-65.